Measuring ligand affinity for a G protein-coupled receptor is often a crucial step in drug discovery. It has been traditionally determined by binding putative new ligands in competition with native ligand labeled with a radioisotope of finite lifetime. Competing instead with a lanthanide-based fluorescent ligand is more attractive due to greater longevity, stability and safety. Here, we have chemically synthesized the 77-residue human C3a protein and conjugated its N-terminus to europium diethylenetriaminepentaacetate to produce a novel fluorescent protein (Eu-DTPA-hC3a). Time-resolved fluorescence analysis has demonstrated that Eu-DTPA-hC3a binds selectively to its cognate G protein coupled receptor C3aR with full agonist activity and similar potency and selectivity as native C3a in inducing calcium secretion and phosphorylation of extracellular signal-regulated kinases in HEK293 cells that stably expressed C3aR. Time-resolved fluorescence analysis for saturation and competitive binding gave a dissociation constant K d 8.7 ± 1.4 nM for Eu-DTPA-hC3a, and binding affinities for hC3a (pK i 8.6 ± 0.2, K i 2.5 nM) and C3aR ligands TR16 (pK i 6.7 ± 0.1, K i 138 nM), BR103 (pK i 6.7 ± 0.1, K i 185 nM), BR111 (pK i 6.3 ± 0.2, K i 544 nM) and SB290157 (pK i 6.3 ± 0.1, K i 517 nM) via displacement of Eu-DTPA-hC3a from hC3aR. The macromolecular conjugate Eu-DTPA-hC3a is a novel non-radioactive probe suitable for studying ligand-C3aR interactions with potential value in accelerating drug development for human C3aR in physiology and disease.
Introduction
The human complement anaphylatoxin C3a is a 77-residue protein derived from proteolytic cleavages of the human complement protein C3 by C3 convertases. C3a mediates a variety of proinflammatory and immunoregulatory functions through binding to its cognate G protein-coupled C3a receptor (C3aR). C3aR is ubiquitously expressed on immune cells, adipocytes, epithelial cells, kidneys, liver, spleen, heart and brain. Due to its extensive distribution, C3aR is linked to physiological responses such as metabolism, inflammation and immunity. 1,2 Apart from modulating immunity, C3aR is implicated in the pathogenesis and progression of various inflammatory diseases including asthma, diet-induced obesity, sepsis, colitis and arthritis. 3-6 However, the biological role and interaction of C3a and C3aR-mediated disease pathologies remain to be fully elucidated. The design and development of small potent synthetic molecules that can selectively target C3aR is required to interrogate and potentially treat C3aR-mediated diseases.
Biophysical binding assays that interrogate C3aR-ligand interactions are essential analytical tools to discover potent C3aR modulators. We have previously employed traditional radioisotope binding assays using [ 125 I]-C3a as a label to study C3aR binding affinity of a series of small ligands capable of mimicking C3a and acting as effective antagonists or agonists of C3aR. 7,8 However, the short half-life of [ 125 I]-C3a and restrictions associated with manipulation of the radionuclide have limited the practicability of this assay, prompting us to pursue alternative methods. Lanthanides such as, europium, samarium and terbium are rareearth metals regarded as attractive alternatives to organic fluorescent molecules and radioactive labeling probes. They display unique fluorescence properties, such as long lifetime of luminescence (µs-ms), which allows highly sensitive detection of biological probes in complex environments by time-resolved fluorescence spectroscopy; a large Stokes shift (~150 nm) which minimizes emission/excitation overlap; and narrow emission peaks (10-20 nm) which collectively contribute to increase signal-to-noise ratio and sensitivity. 9,10 Together with the widely used dissociation enhanced lanthanide fluoroimmunoassay (DELFIA) system, the bound lanthanide on the receptor is dissociated under low pH to give a highly stable fluorescent signal. 11 Based on these advantageous analytical properties of lanthanide-based fluorophores, we sought to develop a novel human C3a probe labeled with a Eu 3+ chelate for use in timeresolved fluorescence binding assays for the screening of C3aR interacting molecules. Herein, we apply the native chemical ligation (NCL) approach 12 to synthesize full-length human C3a specifically modified at the N-terminus by appending diethylenetriaminepentaacetic acid (DTPA), 13 a known chelating ligand for europium (Eu-DTPA-hC3a, Figure 1 ). Next, we validated its functional profile by measuring intracellular calcium release and phosphorylation of extracellular signal-regulated kinase (ERK1/2) in pharmacological assays. We also demonstrated saturation and competitive binding for the novel Eu-DTPA-hC3a in competition with human C3a and known C3aR-specific small molecule ligands (TR16, BR103, BR111 and SB290157). The results establish that Eu-DTPA-hC3a retains the same pharmacological properties as native human C3a, inducing full C3aR activation, competitively binding to C3aR, and competing like C3a with binding by four small molecule agonists and antagonists.
Results and Discussion

Chemical synthesis of the novel Eu-DTPA-hC3a
Human C3a is composed of 77 amino acid residues and contains three intramolecular disulfide bonds ( Figure 1 ). According to Ghassemian et al, synthetic access to full length linear C3a molecule is better achieved using a fragment ligation approach due to its extended sequence. 12 Synthetic peptide segments can be readily prepared using an automated peptide synthesizer employing standard Fmoc protected amino acids and established solid support detachment procedures. We therefore sought to construct synthetic human C3a using a NCL approach suitable for automated Fmoc-chemistry, based on sequential ligation of C-terminally modified peptide hydrazides developed by the Liu group 14 . DTPA was chosen as a chelating ligand due to its high affinity for europium, excellent solubility, and compatibility with NCL methods and C3a folding steps. 13 The positioning of the Eu-DTPA complex at the N-terminus of human C3a was designed so as not to interfere with the key C-terminal effector or activating region of C3a.
The human C3a sequence was divided into three peptide fragments: DTPA-C3a[1-22]-NHNH 2 (1), H-C3a[23-48]-NHNH 2 (2) and H-C3a[49-77]-OH (3), which were individually prepared on resin by standard Fmoc-SPPS using a peptide synthesizer. Fragment 1 and 2 were assembled on a hydrazine-modified trityl resin, 15 while fragment 3 was built on a 2-Cl-trityl solid support. DTPA was attached to the N-terminus of fragment 1 using DTPA anhydride via a previously described method. 16 While fragments 1 and 3 were obtained in good yield and purity, fragment 2 could not be readily isolated after a troublesome synthesis by Fmoc-SPPS. Therefore, we instead adopted a Boc-SPPS method previously reported by us 12 to build the second fragment with higher efficiency, as the thioester Thz 23 -C3a[24-48]-COSR (4). Before NCL, the C-terminal hydrazide of 1 was transformed into a reactive thioester upon activation with NaNO 2 and reaction with Folding of the C3a derivative was carried out in the presence of a glutathione redox system 12 to give oxidized DTPA-C3a 8 (MS: expected mass: 9463.0, observed mass: 9464.8, Figure S2 ). Finally, Eu 3+ complexation was achieved by treating peptide 8 with three equivalents of EuCl 3 in ammonium acetate buffer to give pure folded Eu-DTPA-hC3a ( Figure   1 ). Europium complexation was appropriately performed as the last step of the synthesis, since europium chelation is not compatible with acidic RP-HPLC conditions.
Pharmacological validation of Eu-DTPA-hC3a as a C3aR agonist
To characterize the potency and specificity of synthetic Eu-DTPA-hC3a, concentrationdependent intracellular calcium mobilization was determined on HEK293 cells stably transfected with human Gα 16 and human C3aR (HEK293 Gα 16 -C3aR). Gα 16 belongs to the Gα q protein family, which mediates the activation of phospholipase C leading to the subsequent inositol triphosphate-stimulated mobilization of intracellular calcium from the endoplasmic reticulum. 17 Gα 16 proteins are widely used in high-throughput fluorometric calcium imaging assays for the screening of new GPCR ligands. 18 Furthermore, we have previously characterized C3aR ligands using intracellular calcium mobilization 7,8 and previous studies have also overexpressed Gα 16 to examine the functional activity of human C3aR using an intracellular calcium mobilization assay. 19 Based on concentration-dependent curves, Eu-DTPA-hC3a (pEC 50 8.2 ± 0.1, EC 50 6 nM) and C3a (pEC 50 8.5 ± 0.1, EC 50 3 nM) demonstrated very similar full agonist activity and comparable potency in inducing C3aR-mediated intracellular calcium mobilization ( Figure   2A ). Hence, the addition of Eu-DPTA to the N-terminus of C3a did not interfere with the ability of the protein to act as a full agonist at C3aR. To establish whether Eu-DTPA-hC3a was specific for C3aR, and that the intracellular calcium mobilization was not an off-target activation of other endogenous GPCRs, both Eu-DTPA-hC3a and C3a were tested on HEK293 cells transfected with empty vector (HEK293 Gα 16 cells). Even at a high concentration of 300 nM, Eu-DTPA-hC3a failed to induce any intracellular calcium mobilization in HEK293 Gα 16 cells ( Figure 2B ). These results indicate that the novel conjugate Eu-DTPA-hC3a is a full agonist in mediating intracellular calcium mobilization, while retaining its native specificity for human C3aR. Eu-DTPA-hC3a (100 nM) or C3a (100 nM) at different time points, as ERK1/2 phosphorylation can be rapid or delayed depending on the nature of the ligand, cell type, receptor and signaling pathway being examined. 20 Both Eu-DTPA-hC3a and hC3a showed similar temporal profiles, with maximum phosphorylation of ERK1/2 at 3 min before returning to basal levels at 120 min ( Figure 3A) . Concentration-dependent curves of Eu-DTPA-hC3a versus C3a also demonstrated similar agonist profiles in C3aR-mediated ERK1/2 phosphorylation ( Figure 3B ). Eu-DTPA-hC3a
(pEC 50 8.8 ± 0.1, EC 50 1 nM) showed similar full agonist activity as C3a (pEC 50 9.0 ± 0.1, EC 50 0.9 nM). Consistent with the results from the intracellular calcium mobilization assay ( Figure   2 ), Eu-DTPA-hC3a exhibits similar agonist and temporal profiles as C3a in inducing phosphorylation of ERK1/2. These results further confirmed that incorporating the Eu-DPTA complex onto the N-terminus of human C3a does not interfere with potency, selectivity or pharmacological properties mediated by C3a through its receptor human C3aR.
Saturation and competitive binding of C3aR using the novel Eu-DTPA-hC3a
Ligand affinity plays a critical role in GPCR drug design and development, 21 physiological context, primary human peripheral blood mononuclear cells (PBMC) from buffy coats were used for competitive binding assays with human C3a (IC 50 1.2 nM-2.7 nM) ( Figure   5A and Figure S3 ). The specificity of Eu-DTPA-hC3a to C3aR was again confirmed using HEK293 Gα 16 -C3aR and HEK293 Gα 16 cells in a competitive binding assay with C3a ( Figure   5B ). HEK293 Gα 16 -C3aR cells yielded a typical sigmoidal competitive curve with K i 2.5 nM, while < 10% of Eu-DTPA-hC3a was bound on HEK293 Gα 16 cells ( Figure 5B ). Consistent with the intracellular calcium mobilization assay (Figure 2) , Eu-DTPA-hC3a is specific and requires C3aR for binding to the cells and for intracellular signaling. Competitive binding experiments were performed on HEK293 Gα 16 -C3aR cells using a single concentration of Eu-DTPA-hC3a (2 nM) in the presence of increasing concentrations of C3aR or C5aR ligand. Cells were incubated with Eu-DTPA-hC3a and C3aR or C5aR ligand for 60 min at room temperature with shaking. Binding affinities of C3a (pK i 8.6 ± 0.2, K i 2.5 nM), TR16 (pEC 50 6.7 ± 0.1, K i 138 nM), BR103 (pK i 6.7 ± 0.1, EC 50 185 nM), BR111 (pK i 6.3 ± 0.2, K i 544 nM), SB290157 (pK i 6.3 ± 0.1, K i 517 nM) and 3D53 (pK i >4.5, K i >30 µM) as measured by the displacement of Eu-DTPA-hC3a (2 nM). Error bars represent mean ± SEM of ≥ 3 independent experiments.
Eu-DTPA-hC3a was also additionally validated in competitive binding experiments with known C3aR-specific ligands (TR16, 7 BR103, 27 SB290157 28 and BR111 29 ) ( Figure S4 ) on HEK293 Gα 16 -C3aR cells ( Figure 5C ). The K i values for TR16, BR103, BR111 and SB290157
were 138 nM, 185 nM, 544 nM and 514 nM, respectively. As a control, the C5aR specific and potent antagonist, 3D53, which does not bind to or activate C3aR [30] [31] [32] [33] showed no competitive binding with Eu-DTPA-hC3a even at the highest concentration of 30 µM. We have previously It is estimated that about 30% of marketed drugs target GPCRs or GPCR-mediated mechanisms. 35 The evaluation of the ligand-receptor affinity using labeled probes is therefore essential for drug development and discovery. An ideal label should not alter the intrinsic bioactivity and pharmacological properties of the ligand, should be cost-effective, easy to operate and offer good signal-to-noise ratio. Radioisotopes such as 125 I or 3 H are widely used as labels without significantly affecting binding properties of the ligand, however the high cost,
limited shelf life due to isotope decay, limitations on how they are used, and potential health hazards, are drawbacks of radiolabeled ligand binding assays. The use of lanthanide-based fluorophores, on the other hand, overcomes most of these disadvantages, offering a costeffective and user-friendly probe with a considerably enhanced signal-to-noise ratio. 36 In conclusion, this study has successfully developed a novel Eu-DTPA-hC3a bioconjugate using chemical synthesis. Human C3a protein was synthesized and specifically conjugated at the N-terminus with a Eu-DTPA complex. The DTPA chelator was unaltered during all steps of synthesis and did not interfere with oxidative protein folding, allowing formation of a functionally active C3a protein that behaved as a full agonist at the C3a receptor.
The novel Eu-DTPA-hC3a bioconjugate showed no discernable differences in potency, specificity and pharmacological profiles compared to native C3a. The development of this nonradioisotope alternative for a C3aR-ligand binding assay can help confirm hC3aR binding of other short peptides, such as casoxin C, oryzatensin and TLQP-21 which have been reported to be ligands for C3aR. [37] [38] [39] [40] It could also potentially accelerate the design and development of potent and selective small molecules to elucidate and modulate C3aR-mediated physiology and disease pathology.
Experimental Procedures
Solid-phase peptide synthesis (SPPS)
The human C3a sequence was assembled from three synthetic segments: DTPA-C3a[1-22]-NHNH 2 (1), Thz 23 -C3a[24-48]-COS-CH 2 CH 2 CO-Arg (4) 12 and H-C3a[49-77]-OH (3).
Peptides 1 and 3 were synthesized on solid support by Fmoc-based SPPS on an automated peptide synthesizer (Symphony, Protein Technologies) using a standard HCTU/DIPEA activation protocol and Fmoc-protected amino acids. 41 Hydrazide-modified peptide 1 was assembled on a freshly prepared hydrazine-trityl resin, which was obtained from hydrazination of 2-Cl-trityl resin as previously described. 15 Fragment 3 was assembled directly on a 2-Cl-trityl resin. Coupling of DTPA to the N-terminus of the C3a[1-22] segment was accomplished by treating the dry free-amine peptide-bound resin overnight with a mixture of DTPA anhydride (4 eq) and 1-hydroxybenzotriazole (8 eq) in anhydrous DMSO (preheated to allow reagent dissolution and allowed to react for 30 min before addition to resin). 16 Peptide segments 1 and 3 were cleaved from the solid support by treatment with a cocktail of TFA:triisopropylsilane:water:phenol (88:2:5:5) for 3 h, precipitated in ice-cold diethyl ether, redissolved in a aqueous solution containing 50% acetonitrile/0.01% TFA and lyophilized. confirm the purity and molecular mass of the synthetic peptides (Table S1, Figure S5 ).
Thioester 5. Hydrazide 1 was dissolved at 5 mM concentration in 0.2 M phosphate buffer pH 3.0 containing 6 M guanidine.HCl and cooled to -15 0 C using an ice/salt bath.
NaNO 2 (50 eq) dissolved in minimum water was added dropwise and the resulting mixture was stirred at -15 0 C for 20 min. MESNA (200 eq) was dissolved at 70 mg/mL concentration in 0.2 M phosphate buffer pH 7.0/6M guanidine.HCl and the pH was readjusted to 7 by adding aqueous NaOH. The MESNA solution was then added dropwise to the cold peptide reaction and the resulting mixture was stirred at room temperature for a further 5 minutes. The reaction was quenched by addition of 1% TFA and the resulting thioester 5 was purified by RP-HPLC using a C18 Luna Phenomenex column. MS for 5: found 3136.8, expected 3136.7 Da ( Figure   S5 ).
Assembly of linear DTPA-hC3a (7) by native chemical ligation
Ligation of 4 and 3. Thioester 4 (1 eq) and peptide fragment 3 (1 eq) were dissolved in NCL buffer (50 mM TCEP, 50 mM MPAA, 6 M guanidine.HCl, 0.2 M phosphate buffer pH 7.0) to a 2 mM peptide concentration and the reaction was stirred at room temperature for 5 h.
After that, solid TCEP was added (approximately same mg amount of peptide), the reaction was stirred for further 20 min and finally quenched by addition of 1% TFA. Intermediate 6 was purified by RP-HPLC using a Agilent Zorbax 300SB C18 column as previously described. 12 MS for 6: found 6488.2, expected 6487.6 Da (MS and HPLC data in accordance with ref. 12 ).
Ligation of 6 and 5. Conversion of Thz 23 to Cys 23 in peptide 6 was accomplished by treating 6 with methoxyamine as previously described. 12 The resulting intermediate H-C3a[23-77]-OH was then ligated to 5 using the same conditions as described for the ligation of 4 and 3.
The resulting full-length reduced DTPA-C3a 7 was purified by RP-HPLC using a Agilent Zorbax 300SB C18 column as previously described. 12 MS for 7: found 9471.1, expected 9470.0 Da ( Figure S1 ).
Oxidative folding of DTPA-hC3a
Oxidation of DTPA-hC3a peptide 7 was performed as described. 12 Figure S2 ).
Europium chelation
Oxidized DTPA-hC3a 8 was dissolved in 0.1 M ammonium acetate buffer pH 8.0 at 200 µM concentration and combined with the same volume of 600 µM EuCl 3 (in 0.1 M ammonium acetate buffer) and the resulting solution was stirred at room temperature overnight. Unbound Eu 3+ was removed by solid phase extraction using an Oasis HLB cartridge using the manufacturer instructions. The eluted pure Eu 3+ -labeled peptide was then lyophilized to yield an amorphous white powder. Full conversion to lanthanide-labeled Eu-DTPA-hC3a was confirmed by measuring the mass spectrum of an analytical sample dissolved in acid free 50% acetonitrile and directly injected into the mass spectrometer. A single mass spectrum corresponding to Eu-DTPA-hC3a was found (deconvoluted mass: 9615.5, expected 9614.9; Figure 1 ).
Other C3aR and C5aR ligands
C3aR ligands (TR16 7 , BR103 27 , BR111 29 and SB290157 28 ) and C5aR ligand (3D53 31 )
were synthesized and characterized as previously described ( Figure S4 ).
Cell culture
Cell culture reagents were purchased from Invitrogen. Human embryonic kidney 
Intracellular calcium mobilization assays
Intracellular calcium mobilization assays were performed as previously described. 42 HEK293 Gα 16 µs delay before 620 nm emission.
Data analysis
Data were plotted and analyzed using GraphPad Prism 7 for Mac OS X. EC 50 
